Perhaps other modified or unnatural bases can produce a >20% difference in PSA variant binding, thus leading to a better and more discriminatory PSA test capable of detecting more patients with aggressive prostate cancer in need of earlier cancer treatment (Kote-Jarai et al., 2011; Sullivan et al., 2015). This evidence concerns the gene KLK3 and cancer.